Manufacturers Report No Issues with Supply

NHF will be posting all communications from pharmaceutical companies regarding any potential affects that the COVID-19 pandemic could have on the manufacture and distribution of their products. If you have any questions about your particular product, we urge to you contact your physician or your pharmacy provider directly.
As people are urged by state and local governments and departments of health to self-isolate or quarantine, people who use factor may have questions about their in-home supply. NHF’s Medical and Scientific Advisory Council (MASAC)  recommends  that people keep a one-week supply of medication readily available. Deviations from this that would limit supply to patients, or stockpiling of products by individuals, jeopardize putting all patients at risk unnecessarily.
The Plasma Protein Therapeutics Assocation (PPTA) does not consider the COVID-19 virus to be of concern for the safety of plasma protein therapies manufactured by PPTA member companies.  PPTA’s complete statement is available he r e .
Below are statements from pharmaceutical companies.
“Bayer wants to reassure healthcare providers and patients that rely on our hemophilia A products and associated infusion devices that we currently see no impact to product availability from our U.S. manufacturing operations.”  Read the complete statement here .
Bio Products Laboratory (BPL)
“Patient and product safety continue to be our utmost concern, and our focus, as ever, remains on providing a continuous supply of reliable, high quality plasma-derived products, supporting our patients every day.”  Read the complete statement here .
CSL Behring
“CSL continues to provide an uninterrupted supply of our medicines around the world. As the COVID-19 situation evolves, we are closely tracking any impact it could have on our operations.”  Read the complete statement here .
” Aware that our products and services are important to patients and healthcare providers around the world, we can confirm at this moment there are currently no supply delays or interruptions as a result of the novel coronavirus.”  Read the complete statement here .
Novo Nordisk
“We want to assure patients and health care providers we do not foresee a disruption in our ability to supply the US market with our hemophilia medicines.”  Read the complete statement here.
Medexus Pharma (formerly Aptivo)
“We want to reassure the community that we currently do not see any impact to our ability to supply the US market with our products, including IXINITY and Rasuvo.”  Read the complete statement here.
Statement from  Roche/Genentech regarding its product HEMLIBRA (emicizumab-kxwh).  This statement provides specific reassurance regarding supply chains to its manufacturing facilities worldwide, that they have not identified any critical component that would impact their ability to supply Hemlibra in the future.
“Sanofi does not anticipate shortages for patients resulting from the COVID-19 situation.”   Read the complete statement here.
“Based on our current assessment of our global supply chain, we do not foresee any current risk of disruption resulting from the coronavirus outbreak.”  Read the complete statement here .
NHF will continue to update this story as they receive more information.

Leave a Reply

About Us

The Hemophilia Foundation of Michigan strives to improve the quality of life for all people affected by hemophilia, von Willebrand disease, other coagulation disorders, and related complications.

Recent Posts

It’s a Great Time to Review Your Insurance Plan for 2019

A few things to keep in mind! Do you depend on factor co-pay assistance? If so, you should know that some insurance plans have changed ...
Read More →

What is an Accumulator Adjustment Program?

Beginning January 2018, a few health plans, specifically high deductible plans offered by self-insured employer groups, have changed the way they calculate copays for patients ...
Read More →

Follow Us

Sign up for our Newsletter

Get all the latest updates and news from  HFM

  • This field is for validation purposes and should be left unchanged.
Skip to content